FAQ: CMV Management
Frequently Asked Questions About CMV Management

Released: November 06, 2023

Expiration: September 27, 2024

Hubert H. Fernandez
Hubert H. Fernandez, MD
Atul Humar
Atul Humar, MD
Hannah Imlay
Hannah Imlay, MD, MS
Raymund Razonable
Raymund Razonable, MD
G. Atma Vemulakonda
G. Atma Vemulakonda, MD

Activity

Progress
1
Course Completed

In this episode, Atul Humar, MD, FRCP(C); Hannah Imlay, MD, MS; and Raymund Razonable, MD, discuss cytomegalovirus (CMV) management strategies in solid organ transplantation recipients, including:

  • Evaluation of current data on CMV prevention in liver transplant recipients
  • Practical considerations for switching an institution’s antiviral therapy of choice for primary prophylaxis 
  • Barrier of resistance to antiviral therapies 
  • Factors to consider when deciding CMV treatment duration
  • Use of lymphocyte count to assess CMV cell–mediated immunity